Clinical Trial

A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-CD19-GDT in relapsed/refractory autoimmune diseases.
Trial Details
NCT Number NCT07167537
Lead Sponsor Beijing GoBroad Hospital
Collaborators: Overland Therapeutics
Conditions Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
Enrollment 44 participants
Start Date 2025-10
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-11